Voyager, Neurocrine ink gene-therapy offer

Shares of Voyager Therapeutics Inc.
VYGR,
+10.65%
rallied 35% in premarket buying and selling on Monday soon after the corporation declared a deal with Neurocrine Biosciences Inc.
NBIX,
+.06%
to develop and commercialize gene therapies, which include one that is currently being analyzed as a therapy for Parkinson’s condition. Neurocrine will make a $175 million upfront payment, which includes a $39 million fairness investment decision, with up to $1.5 billion in likely milestones. Voyager’s stock has soared 148.7% more than the past calendar year, whilst the S&P 500
SPX,
+2.28%
is down 17.%.